中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.079 seconds)

    IMMUNOGEN SELECTION
    13.
    发明公开
    IMMUNOGEN SELECTION 审中-公开

    公开(公告)号：US20240321387A1

    公开(公告)日：2024-09-26

    申请号：US18289424

    申请日：2022-05-04

    Applicant: BioNTech SE ,  InstaDeep Ltd

    Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

    IPC: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

    CPC classification number: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

    Abstract: A method is provided for identifying a number of variants of concern of a reference disease associated immunogen. The method uses a language model to perform inference on data representing each of a plurality of variants and data representing the reference immunogen. For each of the plurality of variants and the reference immunogen, a characteristic vector is derived from an output feature map of a hidden layer of the language model. For each of the plurality of variants, a measure of distance is generated for the variant that includes calculating a measure of distance between the characteristic vector of the variant and the characteristic vector of the reference immunogen. A semantic change score is calculated for each variant based on the generated measure of distance for that variant. A variant of the reference immunogen is selected based, at least in part, on the generated the semantic change scores.

    IL2 Agonists
    17.
    发明申请
    IL2 Agonists 有权

    公开(公告)号：US20220356223A1

    公开(公告)日：2022-11-10

    申请号：US17621396

    申请日：2020-06-23

    Applicant: BioNTech SE

    Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Mathias Vormehr ,  Lena Mareen Kranz

    IPC: C07K14/55 ,  A61P35/00

    Abstract: The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the βγ IL2 receptor complex (IL2Rβγ) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the αβγ IL2 receptor complex (IL2αβγ) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

    CORONAVIRUS VACCINE
    19.
    发明公开
    CORONAVIRUS VACCINE 审中-公开

    公开(公告)号：US20230338512A1

    公开(公告)日：2023-10-26

    申请号：US18071499

    申请日：2022-11-29

    Applicant: BioNTech SE

    Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai

    IPC: A61K39/215 ,  A61K45/06

    CPC classification number: A61K39/215 ,  A61K45/06 ,  A61K2039/53

    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

    BINDING AGENTS FOR CORONAVIRUS S PROTEIN
    20.
    发明公开
    BINDING AGENTS FOR CORONAVIRUS S PROTEIN 审中-公开

    公开(公告)号：US20230287088A1

    公开(公告)日：2023-09-14

    申请号：US18019787

    申请日：2021-07-29

    Applicant: BIONTECH SE

    Inventor： Karsten Beckmann ,  Anna Carle ,  Sandra Prassl ,  Claudia Paulmann ,  Christiane Stadler ,  Georg Falck ,  Leyla Fischer ,  Alexander Muik ,  Ugur Sahin ,  Caroline Scharf

    IPC: C07K16/10 ,  A61P31/14

    CPC classification number: C07K16/10 ,  A61P31/14 ,  C07K2317/31 ,  C07K2317/92

    Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.

Patent Agency Ranking